EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Vitro and In Vivo Synergetic Radiotherapy with Gold Nanoparticles and Docetaxel for Pancreatic Cancer

Abdulaziz Alhussan iD, Nolan Jackson, Norman Chow iD, Ermias Gete, Nicole Wretham, Nancy Dos Santos, Wayne Beckham, Cheryl Duzenli iD, Devika B Chithrani iD

Pharmaceutics · 26.05.2024 · 16 (6) · 713

DOI: 10.3390/pharmaceutics16060713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 26.05.2024. Verfasst von Abdulaziz Alhussan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2, Canada. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Kuwait Foundation for the Advancement of Sciences, Nanomedicines Innovation Network Strategic Initiative, Natural Sciences and Engineering Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This research underscores the potential of combining nanotechnology with conventional therapies in cancer treatment, particularly for challenging cases like pancreatic cancer. We aimed to enhance pancreatic cancer treatment by investigating the synergistic effects of gold nanoparticles (GNPs) and docetaxel (DTX) as potential radiosensitizers in radiotherapy (RT) both in vitro and in vivo, utilizing a MIA PaCa-2 monoculture spheroid model and NRG mice subcutaneously implanted with MIA PaCa-2 cells, respectively. Spheroids were treated with GNPs (7.5 μg/mL), DTX (100 nM), and 2 Gy of RT using a 6 MV linear accelerator. In parallel, mice received treatments of GNPs (2 mg/kg), DTX (6 mg/kg), and 5 Gy of RT (6 MV linear accelerator). In vitro results showed that though RT and DTX reduced spheroid size and increased DNA DSBs, the triple combination of DTX/RT/GNPs led to a significant 48% (p = 0.05) decrease in spheroid size and a 45% (p = 0.05) increase in DNA DSBs. In vivo results showed a 20% (p = 0.05) reduction in tumor growth 20 days post-treatment with (GNPs/RT/DTX) and an increase in mice median survival. The triple combination exhibited a synergistic effect, enhancing anticancer efficacy beyond individual treatments, and thus could be employed to improve radiotherapy and potentially reduce adverse effects.

Schlagwörter

Stichwörter der Autor:innen

docetaxelgold nanoparticlesin vivopancreatic cancerradiotherapy

Autor:innen und Institutionen

  • Department of Physics and Astronomy, University of Victoria, Victoria, BC V8P 5C2, Canada.
  • Department of Experimental Therapeutics, British Columbia Cancer-Vancouver, Vancouver, BC V5Z IL3, Canada.
  • Radiation Oncology, British Columbia Cancer-Vancouver, Vancouver, BC V5Z 4E6, Canada.
  • Department of Physics and Astronomy, University of British Columbia, Vancouver, BC V6T 1Z1, Canada.
  • Radiation Oncology, British Columbia Cancer-Victoria, Victoria, BC V8R 6V5, Canada.
  • Center for Advanced Materials and Related Technologies, Department of Chemistry, University of Victoria, Victoria, BC V8P 5C2, Canada.

ORCID-Profile: Abdulaziz Alhussan, Norman Chow, Cheryl Duzenli, Devika B Chithrani

Förderung

  • Kuwait Foundation for the Advancement of Sciences
  • Nanomedicines Innovation Network Strategic Initiative
  • Natural Sciences and Engineering Research Council
  • NanoMedicines Innovation Network Strategic Initiative fund (NMIN-SI)
  • John R. Evans Leaders Fund (JELF)
  • British Columbia Knowledge Development Fund (BCKDF)
  • Discovery Grant from the Natural Sciences and Engineering Research Council of Canada (NSERC)
  • National Institutes of Health (NIH) of the United States of America

Zitieren

APA

Alhussan, A., Jackson, N., Chow, N., Gete, E., Wretham, N., Dos Santos, N., Beckham, W., Duzenli, C., & Chithrani, D. B. (2024). In Vitro and In Vivo Synergetic Radiotherapy with Gold Nanoparticles and Docetaxel for Pancreatic Cancer. Pharmaceutics, 16(6), 713. https://doi.org/10.3390/pharmaceutics16060713

Vancouver

Alhussan A, Jackson N, Chow N, Gete E, Wretham N, Dos Santos N, et al. In Vitro and In Vivo Synergetic Radiotherapy with Gold Nanoparticles and Docetaxel for Pancreatic Cancer. Pharmaceutics. 2024;16(6):713. doi:10.3390/pharmaceutics16060713

BibTeX
@article{Alhussan2024,
  author = {Alhussan, Abdulaziz and Jackson, Nolan and Chow, Norman and Gete, Ermias and Wretham, Nicole and Dos Santos, Nancy and Beckham, Wayne and Duzenli, Cheryl and Chithrani, Devika B},
  title = {In Vitro and In Vivo Synergetic Radiotherapy with Gold Nanoparticles and Docetaxel for Pancreatic Cancer},
  journal = {Pharmaceutics},
  year = {2024},
  volume = {16},
  number = {6},
  pages = {713},
  doi = {10.3390/pharmaceutics16060713}
}
Kostenlos starten →